Conjunctivitis News and Research

RSS

Conjunctivitis is an eye infection that may cause redness and discharge from the eye, sometimes with pain or itching. It can be caused by bacteria or viruses.

Inspire second-quarter total revenue increases 18% to $27.3 million

Inspire Pharmaceuticals, Inc. announced today financial results for the second quarter ended June 30, 2010, reporting a net loss of $8.8 million or ($0.11) per share, an improvement from the second quarter of 2009 during which the Company incurred a net loss of $9.5 million or ($0.17) per share.

5 Aug 2010

Allergan second-quarter diluted EPS increases to $0.78

Allergan, Inc. today announced operating results for the quarter ended June 30, 2010. Allergan also announced that its Board of Directors has declared a second quarter dividend of $0.05 per share, payable on September 7, 2010 to stockholders of record on August 17, 2010.

3 Aug 2010

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo. Furthermore, the safety profile of BDP HFA Nasal Aerosol was similar to placebo.

29 Jul 2010

QLT second-quarter total revenue increases 15.4% to $12.4 million

QLT Inc. today reported financial results for the second quarter ended June 30, 2010. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

27 Jul 2010

Alcon second-quarter global sales increase 12.5% to $1.89 billion

Alcon, Inc. reported that global sales rose 12.5 percent to $1.89 billion for the second quarter of 2010, or 11.3 percent excluding the impact of foreign exchange fluctuations and acquisitions. Revenue from acquisitions added 40 basis points to sales growth in the quarter, while foreign currency fluctuations added 80 basis points of growth.

27 Jul 2010

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

NovaBay Pharmaceuticals, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent will broaden protection for NovaBay's first-in-class Aganocide family of compounds, which are designed to fight infections without causing drug resistance.

15 Jul 2010

Phase 1/2 clinical study of bepotastine besilate nasal spray initiated for seasonal allergic rhinitis

ISTA Pharmaceuticals, Inc., today announced it has initiated a Phase 1/2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group study will evaluate the safety and efficacy of three concentrations of bepotastine besilate, dosed twice daily, in an Environmental Exposure Chamber model of allergic rhinitis caused by natural exposure to seasonal allergens.

14 Jul 2010

bitop's Ectoin allergy nasal spray reduces symptoms of acute allergic rhinitis in two-week crossover study

bitop AG, a biotech company specializing in the development of Ectoin®-containing medical devices, reports that Ectoin allergy nasal spray has been shown to significantly reduce symptoms of acute allergic rhinitis in a two-week observational, randomized, comparative crossover study with 50 patients suffering from acute allergic rhinitis. Based on this study, bitop performed a clinical trial on eyes drops and nasal spray in humans using an environmental exposure chamber (EEC) model.

12 Jul 2010

Caraco Pharmaceutical Laboratories commences shipping azelastine ophthalmic solution

Caraco Pharmaceutical Laboratories, Ltd. has started shipping azelastine ophthalmic solution, 0.05%. This product was recently approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA).

7 Jul 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Inspire Pharmaceuticals, Inc. announced today that data is being presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during an oral presentation and poster presentations at the 33rd Annual European Cystic Fibrosis Society (ECFS) Conference June 16 - 19, 2010 in Valencia, Spain.

18 Jun 2010

Fovea's initiation of Prednisporin Phase 2b clinical testing triggers milestone payment to CombinatoRx

CombinatoRx, Incorporated today announced that it has received a milestone payment from Fovea Pharmaceuticals, a division of Sanofi Aventis, relating to Fovea's initiation of Phase 2b clinical testing of PrednisporinTM (FOV1101) in subjects with persistent allergic conjunctivitis. Prednisporin™ is a CombinatoRx-derived combination drug candidate that was exclusively licensed to Fovea by CombinatoRx.

7 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Allergy sufferers can save out-of-pocket costs by visiting urgent care and retail health clinics instead of ER

In this economy, allergy sufferers are looking for relief from more than sneezing, runny noses, and itchy eyes. And, according to a recent study, they can find relief for both their symptoms and their wallets, saving anywhere from $50 to $400 in out-of-pocket costs per visit if they skip the emergency room and head to urgent care and retail health clinics when they are unable to see their primary physician.

20 May 2010

Scientists present data on denufosol tetrasodium for CF at ATS 2010 International Conference

Inspire Pharmaceuticals, Inc. announced today that Inspire scientists and collaborators will present data on denufosol tetrasodium, an investigational therapy for cystic fibrosis, during an oral presentation at the American Thoracic Society 2010 International Conference May 14 - 19, 2010 in New Orleans, LA.

20 May 2010

FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis

Allergan, Inc. today announced that the United States Food and Drug Administration has approved ZYMAXID (gatifloxacin ophthalmic solution) 0.5%, a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms; Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumonia.

20 May 2010

NovaBay first-quarter net loss increases to $1.6 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported financial results for the first quarter of 2010.

12 May 2010

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).

10 May 2010

Urgent care and retail health clinics can reduce treatment costs for allergy sufferers

10 May 2010

Roche launches cobas(R) 4800 System in Canada for testing CT, NG and HPV

Roche Diagnostics Canada announced today the launch of a new Health Canada approved clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs. The cobas(R) 4800 System combines in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology.

From Roche Sequencing and Life Science 7 May 2010

Conjunctivitis News and Research

Further Reading

Inspire second-quarter total revenue increases 18% to $27.3 million

Allergan second-quarter diluted EPS increases to $0.78

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

QLT second-quarter total revenue increases 15.4% to $12.4 million

Alcon second-quarter global sales increase 12.5% to $1.89 billion

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

Phase 1/2 clinical study of bepotastine besilate nasal spray initiated for seasonal allergic rhinitis

bitop's Ectoin allergy nasal spray reduces symptoms of acute allergic rhinitis in two-week crossover study

Caraco Pharmaceutical Laboratories commences shipping azelastine ophthalmic solution

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Fovea's initiation of Prednisporin Phase 2b clinical testing triggers milestone payment to CombinatoRx

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Allergy sufferers can save out-of-pocket costs by visiting urgent care and retail health clinics instead of ER

Scientists present data on denufosol tetrasodium for CF at ATS 2010 International Conference

FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis

NovaBay first-quarter net loss increases to $1.6 million

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Urgent care and retail health clinics can reduce treatment costs for allergy sufferers

Roche launches cobas(R) 4800 System in Canada for testing CT, NG and HPV

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News